1
TÍTULO: Effect of zamicastat on blood pressure and heart rate response to cold pressor test: A double-blind, randomized, placebo-controlled study in healthy subjects  Full Text
AUTORES: Fonseca, Marlene; Ribeiro, Cheila; Castilla Fernandez, Guillermo; Gama, Helena; Magalhaes, Luis; Henriques, Sara Carolina; Silva, Nuno; Pinto, Filipe; Almeida, Luis; Soares da Silva, Patricio;
PUBLICAÇÃO: 2024, FONTE: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
INDEXADO EM: Scopus WOS
2
TÍTULO: Long-term quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate  Full Text
AUTORES: Krishnaiengar, Suparna R.; Cantu, David; Hall, Diane; Gama, Helena; Pereira, Ana; Grinnell, Todd;
PUBLICAÇÃO: 2023, FONTE: EPILEPSY & BEHAVIOR, VOLUME: 148
INDEXADO EM: Scopus WOS
3
TÍTULO: Long-term therapeutic effect of eslicarbazepine acetate in children: An open-label extension of a cognition study in children aged 6-16 years  Full Text
AUTORES: Veggiotti, P; Jozwiak, S; Kirkham, F; Moreira, J; Pereira, A; Ikedo, F; Gama, H;
PUBLICAÇÃO: 2022, FONTE: EPILEPSY & BEHAVIOR, VOLUME: 127
INDEXADO EM: WOS
4
TÍTULO: The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II  Full Text
AUTORES: Barros, José; Ebersbach, Georg; Lees, Andrew; Tolosa, Eduardo; Ferreira, Joaquim J.; Poewe, Werner; Rascol, Olivier; Stocchi, Fabrizio; Antonini, Angelo; Magalhaes, Diogo; Gama, Helena; Soares da Silva, Patricio;
PUBLICAÇÃO: 2022, FONTE: FRONTIERS IN NEUROLOGY, VOLUME: 13
INDEXADO EM: Scopus WOS CrossRef: 1
5
TÍTULO: Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (>= 60 years) and younger (18-59 years) adults  Full Text
AUTORES: Andermann, E; Rosenfeld, W; Penovich, P; Rogin, J; Cendes, F; Carreno, M; Ramsay, RE; Ben Menachem, E; Gama, H; Rocha, F; Soares da Silva, P; Tosiello, R; Blum, D; Grinnell, T;
PUBLICAÇÃO: 2021, FONTE: EPILEPSY RESEARCH, VOLUME: 169
INDEXADO EM: Scopus WOS
6
TÍTULO: The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II  Full Text
AUTORES: Barros, José; Ebersbach, G; Lees, A; Tolosa, E; Ferreira, JJ; Poewe, W; Rascol, O; Stocchi, F; Antonini, A; Magalhaes, D; Gama, H; Soares Da Silva, P;
PUBLICAÇÃO: 2021, FONTE: FRONTIERS IN NEUROLOGY, VOLUME: 12
INDEXADO EM: Scopus WOS CrossRef: 9
7
TÍTULO: Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate  Full Text
AUTORES: Joanne Rogin; Trevor Resnick; Laura Strom; Elinor Ben Menachem; Silvia Kochen; David Blum; Helena Gama; Patricio Soares da Silva; Yan Li; Todd Grinnell;
PUBLICAÇÃO: 2020, FONTE: ACTA NEUROLOGICA SCANDINAVICA, VOLUME: 141, NÚMERO: 5
INDEXADO EM: Scopus WOS
8
TÍTULO: A Randomized, Double-Blind, Placebo-Controlled and Open-Label, Active-Controlled, 4-Period Crossover Trial to Evaluate the Effect of Zamicastat on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions
AUTORES: Gama, H; Magalhaes, L; Santos, A; Soares Da Silva, P;
PUBLICAÇÃO: 2020, FONTE: International Conference of the American-Thoracic-Society in AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, VOLUME: 201
INDEXADO EM: WOS
9
TÍTULO: Safety Profile of Opicapone in the Management of Parkinson's Disease
AUTORES: Lees, A; Ferreira, JJ; Rocha, JF; Rascol, O; Poewe, W; Gama, H; Soares da Silva, P;
PUBLICAÇÃO: 2019, FONTE: JOURNAL OF PARKINSONS DISEASE, VOLUME: 9, NÚMERO: 4
INDEXADO EM: Scopus WOS CrossRef: 24
10
TÍTULO: Influence of of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials  Full Text
AUTORES: Gregory Krauss; Victor Biton; Jay H Harvey; Christian Elger; Eugen Trinka; Patricio Soares da Silva; Helena Gama; Hailong L Cheng; Todd Grinnell; David Blum;
PUBLICAÇÃO: 2018, FONTE: EPILEPSY RESEARCH, VOLUME: 139
INDEXADO EM: Scopus WOS
Página 1 de 3. Total de resultados: 28.